Compare Stocks

Date Range: 

 Horizon Therapeutics PublicCureVacMERCK Kommanditgesellschaft auf AktienGenmab A/SCatalent
SymbolNASDAQ:HZNPNASDAQ:CVACOTCMKTS:MKGAFOTCMKTS:GNMSFNYSE:CTLT
Price Information
Current Price$87.93$100.40$174.00$381.17$107.56
52 Week RangeBuyHoldN/ABuyBuy
MarketRank™
Overall Score2.80.70.50.61.7
Analysis Score4.51.20.00.02.4
Community Score3.32.32.31.92.4
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.00.01.7
Earnings & Valuation Score4.40.00.01.31.9
Analyst Ratings
Consensus RecommendationBuyHoldN/ABuyBuy
Consensus Price Target$111.36$58.33N/AN/A$125.13
% Upside from Price Target26.65% upside-41.90% downsideN/AN/A16.33% upside
Trade Information
Market Cap$19.70 billion$18.77 billion$22.49 billion$23.51 billion$18.32 billion
Beta1.15N/A0.70.831.5
Average Volume1,849,183970,1664611,2551,066,246
Sales & Book Value
Annual Revenue$1.30 billionN/A$18.09 billion$804.57 million$3.09 billion
Price / Sales15.16N/A1.2429.235.92
Cashflow$3.96 per shareN/A$37.02 per share$4.97 per share$3.49 per share
Price / Cash22.22N/A4.7076.6430.82
Book Value$11.67 per shareN/A$155.24 per share$34.13 per share$18.71 per share
Price / Book7.53N/A1.1211.175.75
Profitability
Net Income$573.02 millionN/A$1.48 billion$324.68 million$173 million
EPS$1.94N/AN/AN/A$1.88
Trailing P/E Ratio24.020.000.005.4168.51
Forward P/E Ratio20.45N/A38.83
P/E Growth0.59N/AN/AN/A2.68
Net Margins43.55%N/A10.92%51.02%9.25%
Return on Equity (ROE)25.66%N/A14.29%34.38%14.20%
Return on Assets (ROA)14.19%N/A5.90%30.65%4.83%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.26%N/AN/AN/A0.97%
Current Ratio3.49%N/A1.06%8.64%2.56%
Quick Ratio3.39%N/A0.70%8.64%2.14%
Ownership Information
Institutional Ownership Percentage88.59%4.32%N/A0.04%97.84%
Insider Ownership Percentage4.30%N/AN/AN/A1.00%
Miscellaneous
Employees1,39550058,12778114,000
Shares Outstanding224.07 million186.91 million129.24 million61.69 million170.34 million
Next Earnings Date8/4/2021 (Estimated)N/A5/13/2021 (Estimated)8/11/2021 (Estimated)8/30/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Catalent, Inc. (NYSE:CTLT) Expected to Post Earnings of $1.12 Per ShareCatalent, Inc. (NYSE:CTLT) Expected to Post Earnings of $1.12 Per Share
americanbankingnews.com - May 8 at 5:16 AM
Catalent acquires facility in Belgium for commercial-scale plasmid DNA manufacturing - NJBIZCatalent acquires facility in Belgium for commercial-scale plasmid DNA manufacturing - NJBIZ
njbiz.com - May 7 at 11:59 PM
Catalent, Inc. to Present at the BofA Securities 2021 Health Care Conference - StreetInsider.comCatalent, Inc. to Present at the BofA Securities 2021 Health Care Conference - StreetInsider.com
streetinsider.com - May 7 at 6:58 PM
Catalent, Inc. to Present at the BofA Securities 2021 Health Care Conference - StockhouseCatalent, Inc. to Present at the BofA Securities 2021 Health Care Conference - Stockhouse
stockhouse.com - May 7 at 1:58 PM
Catalent continues to grow Center of Excellence in Belgium with latest acquisition - ROI-NJ.comCatalent continues to grow Center of Excellence in Belgium with latest acquisition - ROI-NJ.com
roi-nj.com - May 7 at 1:58 PM
Cignas Strong Performance Across Businesses Drive Q1 Earnings Beat; Raises 2021 GuidanceCigna's Strong Performance Across Businesses Drive Q1 Earnings Beat; Raises 2021 Guidance
finance.yahoo.com - May 7 at 1:58 PM
Catalent, Inc. to Present at the BofA Securities 2021 Health Care ConferenceCatalent, Inc. to Present at the BofA Securities 2021 Health Care Conference
finance.yahoo.com - May 7 at 1:58 PM
Gallery: Protesters stage “Free the Vaccine” rally outside Catalent – The Bloomingtonian - The BloomingtonianGallery: Protesters stage “Free the Vaccine” rally outside Catalent – The Bloomingtonian - The Bloomingtonian
bloomingtonian.com - May 6 at 10:56 PM
Fill & finish drive Catalents biologics biz - BoProcess Insider - BioProcess InsiderFill & finish drive Catalent's biologics biz - BoProcess Insider - BioProcess Insider
bioprocessintl.com - May 6 at 5:56 PM
Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campus - FiercePharmaCatalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campus - FiercePharma
fiercepharma.com - May 6 at 5:56 PM
Catalent Acquires Additional Facility at its Gosselies, Belgium Campus for Commercial-Scale Plasmid DNA Manufacturing - Yahoo FinanceCatalent Acquires Additional Facility at its Gosselies, Belgium Campus for Commercial-Scale Plasmid DNA Manufacturing - Yahoo Finance
finance.yahoo.com - May 6 at 12:55 PM
Catalent, Inc. 2021 Q3 - Results - Earnings Call PresentationCatalent, Inc. 2021 Q3 - Results - Earnings Call Presentation
seekingalpha.com - May 6 at 10:24 AM
Analysts Have Conflicting Sentiments on These Healthcare Companies: Premier (PINC), Theravance Biopharma (TBPH) and Catalent (CTLT) - Smarter AnalystAnalysts Have Conflicting Sentiments on These Healthcare Companies: Premier (PINC), Theravance Biopharma (TBPH) and Catalent (CTLT) - Smarter Analyst
smarteranalyst.com - May 6 at 7:55 AM
Catalent (NYSE:CTLT) Releases FY 2021 Earnings GuidanceCatalent (NYSE:CTLT) Releases FY 2021 Earnings Guidance
americanbankingnews.com - May 4 at 11:30 PM
Catalent Inc (CTLT) Q3 2021 Earnings Call Transcript - The Motley FoolCatalent Inc (CTLT) Q3 2021 Earnings Call Transcript - The Motley Fool
fool.com - May 4 at 10:49 PM
Catalent: Fiscal Q3 Earnings Snapshot - San Antonio Express-NewsCatalent: Fiscal Q3 Earnings Snapshot - San Antonio Express-News
expressnews.com - May 4 at 10:49 PM
Catalent (CTLT) Tops Q3 Earnings and Revenue Estimates - Yahoo FinanceCatalent (CTLT) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 4 at 5:49 PM
Catalent, Inc. (CTLT) CEO John Chiminski On Q3 2021 Results - Earnings Call Transcript - Seeking AlphaCatalent, Inc. (CTLT) CEO John Chiminski On Q3 2021 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 4 at 5:49 PM
Catalent Inc (CTLT) Q3 2021 Earnings Call TranscriptCatalent Inc (CTLT) Q3 2021 Earnings Call Transcript
finance.yahoo.com - May 4 at 5:48 PM
Catalent (NYSE:CTLT) Posts Quarterly  Earnings Results, Beats Estimates By $0.09 EPSCatalent (NYSE:CTLT) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS
americanbankingnews.com - May 4 at 4:29 PM
Catalent (NYSE:CTLT)  Shares Down 8.8% Catalent (NYSE:CTLT) Shares Down 8.8%
americanbankingnews.com - May 4 at 1:16 PM
Catalent: Q3 Earnings Insights - BenzingaCatalent: Q3 Earnings Insights - Benzinga
benzinga.com - May 4 at 12:48 PM
Should Drug Manufacturers - Specialty & Generic Stock Catalent Inc (CTLT) Be in Your Portfolio Tuesday? - InvestorsObserverShould Drug Manufacturers - Specialty & Generic Stock Catalent Inc (CTLT) Be in Your Portfolio Tuesday? - InvestorsObserver
investorsobserver.com - May 4 at 12:48 PM
Catalent (CTLT) Tops Q3 Earnings and Revenue EstimatesCatalent (CTLT) Tops Q3 Earnings and Revenue Estimates
finance.yahoo.com - May 4 at 12:48 PM
Catalent, Inc. Reports Q3 EPS $1.27 - CMLViz.com - CML NewsCatalent, Inc. Reports Q3 EPS $1.27 - CMLViz.com - CML News
cmlviz.com - May 4 at 7:47 AM
Catalent (NYSE:CTLT) Upgraded to "Buy" by Zacks Investment ResearchCatalent (NYSE:CTLT) Upgraded to "Buy" by Zacks Investment Research
marketbeat.com - April 27 at 8:48 PM
DateCompanyBrokerageAction
3/29/2021Horizon Therapeutics PublicMorgan StanleyReiterated Rating
3/25/2021Horizon Therapeutics PublicGuggenheimBoost Price Target
3/24/2021Horizon Therapeutics PublicCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated Rating
3/23/2021Horizon Therapeutics PublicStifel NicolausBoost Price Target
3/19/2021Horizon Therapeutics PublicJefferies Financial GroupReiterated Rating
3/17/2021Horizon Therapeutics PublicWolfe ResearchInitiated Coverage
2/9/2021Horizon Therapeutics PublicBank of AmericaReiterated Rating
11/3/2020Horizon Therapeutics PublicBMO Capital MarketsBoost Price Target
9/9/2020Horizon Therapeutics PublicJPMorgan Chase & Co.Initiated Coverage
7/22/2020Horizon Therapeutics PublicPiper SandlerBoost Price Target
4/26/2021CureVacCredit Suisse GroupInitiated Coverage
11/17/2020CureVacBerenberg BankReiterated Rating
11/25/2020Genmab A/SUBS GroupReiterated Rating
8/13/2020Genmab A/SBarclaysReiterated Rating
10/1/2018Genmab A/SHC WainwrightReiterated Rating
3/2/2021CatalentArgusBoost Price Target
2/3/2021CatalentRoyal Bank of CanadaBoost Price Target
11/5/2020CatalentDeutsche Bank AktiengesellschaftBoost Price Target
11/4/2020CatalentRobert W. BairdBoost Price Target
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.